Skip to main content
OpenTrials
Completed

NCT Number: NCT07270146

Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency

The main function of Guilu Erxian Oral Liquid is to warm the shen (kindney) and replenish essence. It is used for chronic shen (kindney) deficiency, waist and knee weakness, spermatorrhea and impotence. The treatment of deficiency of kidney essence and asthenospermia is to invigorate the shen (kindney) and replenish the essence, nourish the shen (kindney) and assist the essence. The idea of combining traditional Chinese and western medicine is to move the yang and calm the yin, and traditional Chinese medicine is mainly to invigorate the shen (kindney) and replenish the essence. In order to better provide the basis for clinical medication and meet the treatment needs of oligozoospermia and asthenospermia, this trial is intended to evaluate the effectiveness and safety of Guilu Erxian oral liquid in treating oligozoospermia and asthenospermia with Syndrome of Shen (Kidney) Essence Deficiency subjects.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Married men aged 22 to 40;
  • Meet the diagnostic criteria of male infertility;
  • Meet the diagnostic criteria for mild and moderate oligozoospermia, asthenospermia and oligoasthenospermia;
  • Meet the TCM syndrome differentiation standard of Shen (kidney) essence deficiency syndrome;
  • Sign the informed consent form voluntarily.

Exclusion criteria

  • Infertility due to chromosome abnormalities (such as Roche heterotopia, Y chromosome microdeletion, etc.);
  • Varicocele or cryptorchidism;
  • Diseases affecting semen quality such as orchitis, epididymitis, mycoplasma and chlamydia infection;
  • Anejaculation, retrograde ejaculation and other sexual dysfunction;
  • Severe liver and kidney dysfunction (alanine aminotransferase (ALT)>1.5 × ULN, aspartate aminotransferase (AST)>1.5 × ULN, blood urea nitrogen (BUN)>2 × ULN, Cr>1 × ULN), disease of cardiovascular and cerebrovascular system, disease of hematopoietic system;
  • Hypertension (systolic blood pressure > 160 mmHg and / or diastolic blood pressure > 100 mmHg) or diabetes (fasting blood glucose > 7mmol / L) with poor drug control;
  • Serious mental illness, accompanied by mental disorder or loss of self-care ability;
  • Those who are allergic to the test drug;
  • Those who have long term bad habits such as smoking and drinking, which may affect fertility, or those who cannot ban smoking and drinking during the test, the specific criteria are as follows:

①History of smoking: Those who have smoked more than 5 cigarettes per day in the past 6 months;

②History of drinking: in the past 6 months, the average daily consumption of alcohol exceeded the following standards: 570 ml of beer, 200 ml of wine or 60 ml of spirit, each containing about 20 g of alcohol;

  • Those who have been unable to take the test drug in the past or have intolerable adverse reactions;
  • Those who used drugs to improve or affect sperm concentration or motility 1 month before screening;
  • Those who have participated in other clinical trials within 3 months before screening;
  • According to the judgment of the investigator, there are other persons who are not suitable to participate in this clinical trial.

Treatment and study plan

Guilu Erxian Oral Liquid

Drug

Guilu Erxian Oral Liquid+Wuzi Yanzong Oral Liquid Simulator

Wuzi Yanzong oral liquid

Drug

Wuzi Yanzong oral liquid+Guilu Erxian oral liquid simulator

Primary outcomes

  1. Total number of anterograde motile sperm (TPMSC)

    Time frame: 4,8,12 weeks after medical treatment

    Total number of anterograde motile sperm (TPMSC), the change value from the baseline

Secondary outcomes

  1. Semen routine parameters: sperm concentration (SC), total sperm count (SPE-C), percentage of sperm forward movement (PR,%), total sperm vitality (PR+NP,%)

    Time frame: 4,8,12 weeks after medical treatment

    Semen routine parameters: sperm concentration (SC), total sperm count (SPE-C), percentage of sperm forward movement (PR,%), total sperm vitality (PR+NP,%), changes from baseline

  2. TCM syndrome score

    Time frame: 4,8,12 weeks after medical treatment

    TCM syndrome score: the change value from the baseline

  3. Pregnancy rate of spouse/partner

    Time frame: 4,8,12,24 weeks after medical treatment

    Pregnancy rate of the subject's spouse/partner

  4. Male reproductive endocrine hormones: testosterone (T), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL)

    Time frame: 12 weeks after medical treatment

    Male reproductive endocrine hormones: testosterone (T), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), the change value compared with the baseline (when it is conditional and necessary to conduct male reproductive endocrine hormone testing)

  5. Sperm DNA fragment index, which is used for sperm DNA integrity analysis

    Time frame: 12 weeks after medical treatment

    Sperm DNA fragment index, which is used for sperm DNA integrity analysis, the change value compared with the baseline (when DFI detection is conditional and necessary)

Sponsors and collaborators

Lead sponsor

DongE E Jiao Coporation Limited

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Positive Drug Controlled Clinical Trial on the Efficacy and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Dec 8, 2025
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.